1. Market Research
  2. > Blood Coagulation - Pipeline Review, H2 2013

Blood Coagulation - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 80 pages

Blood Coagulation - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Blood Coagulation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Blood Coagulation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Coagulation. Blood Coagulation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Blood Coagulation.
- A review of the Blood Coagulation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Blood Coagulation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Blood Coagulation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Blood Coagulation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Blood Coagulation - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Blood Coagulation Overview 8
Therapeutics Development 9
Pipeline Products for Blood Coagulation - Overview 9
Pipeline Products for Blood Coagulation - Comparative Analysis 10
Blood Coagulation - Therapeutics under Development by Companies 11
Blood Coagulation - Therapeutics under Investigation by Universities/Institutes 13
Blood Coagulation - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Blood Coagulation - Products under Development by Companies 17
Blood Coagulation - Products under Investigation by Universities/Institutes 18
Blood Coagulation - Companies Involved in Therapeutics Development 19
Bayer AG 19
CSL Limited 20
LG Life Sciences, Ltd. 21
ARCA biopharma, Inc. 22
LegoChem Biosciences, Inc 23
Zedira GmbH 24
Navya Biologicals Pvt Ltd 25
Arromax Pharmatech, Co. Ltd. 26
China Grand Wuhan General Pharmaceutical Research Institute 27
Blood Coagulation - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Assessment by Therapeutic Class 37
Drug Profiles 40
XY-0915-BF-2 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
rivaroxaban - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
NU-172 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
XY-0902-LB-2 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
CSL-650 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
AMX-2004 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
LB-30870 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
NAVOH-002 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
DIS-COM-COAG - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Recombinant Simukunin - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Drugs for Thrombosis and Blood Coagulation - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Small Molecules to Inhibit Factor XIa for Thrombosis and Blood Coagulation - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Blood Factor VIa/XIa Inhibitor - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Aegyptin - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
ZED-1301 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Blood Coagulation - Recent Pipeline Updates 59
Blood Coagulation - Dormant Projects 70
Blood Coagulation - Discontinued Products 71
Blood Coagulation - Product Development Milestones 72
Featured News and Press Releases 72
Aug 29, 2013: Octapharma USA Announces Octaplas Now Available for U.S. Patients 72
Jul 02, 2013: Prothrombin Complex Concentrates Can Reverse Blood Thinning Effects of XARELTO 72
Mar 27, 2013: Pozen Submits New Drug Application For PA32540 74
Oct 31, 2012: Asahi Kasei Pharma America Initiates Phase III Clinical Trial For ART-123 In Severe Sepsis Patients With Coagulopathy 75
Jul 04, 2012: Platelet Drug Shows Clinical Benefits For Severe, Unresponsive Aplastic Anemia 75
Feb 28, 2012: Thrombotech Receives FDA Approval For Phase IIa Trial Of THR-18 In US 76
Jun 29, 2011: Kyowa Hakko Kirin Initiates Phase III Clinical Study Of KW-3357 In Japan 76
Nov 15, 2010: Portola Announces Factor Xa Inhibitor Antidote Reverses Anticoagulant Activity Of Factor Xa Inhibitors 77
Apr 29, 2010: Artisan Pharma, Inc. Completes Enrollment In 750-patient Phase IIb Study Of ART-123 In Sepsis Patients With DIC 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80



List of Tables

Number of Products under Development for Blood Coagulation, H2 2013 9
Number of Products under Development for Blood Coagulation - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Stage Development, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 18
Blood Coagulation - Pipeline by Bayer AG, H2 2013 19
Blood Coagulation - Pipeline by CSL Limited, H2 2013 20
Blood Coagulation - Pipeline by LG Life Sciences, Ltd., H2 2013 21
Blood Coagulation - Pipeline by ARCA biopharma, Inc., H2 2013 22
Blood Coagulation - Pipeline by LegoChem Biosciences, Inc, H2 2013 23
Blood Coagulation - Pipeline by Zedira GmbH, H2 2013 24
Blood Coagulation - Pipeline by Navya Biologicals Pvt Ltd, H2 2013 25
Blood Coagulation - Pipeline by Arromax Pharmatech, Co. Ltd., H2 2013 26
Blood Coagulation - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H2 2013 27
Assessment by Monotherapy Products, H2 2013 28
Number of Products by Stage and Target, H2 2013 30
Number of Products by Stage and Mechanism of Action, H2 2013 32
Number of Products by Stage and Route of Administration, H2 2013 34
Number of Products by Stage and Molecule Type, H2 2013 36
Number of Products by Stage and Therapeutic Class, H2 2013 39
Blood Coagulation Therapeutics - Recent Pipeline Updates, H2 2013 59
Blood Coagulation - Dormant Projects, H2 2013 70
Blood Coagulation - Discontinued Products, H2 2013 71



List of Figures

Number of Products under Development for Blood Coagulation, H2 2013 9
Number of Products under Development for Blood Coagulation - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Early Stage Products, H2 2013 16
Assessment by Monotherapy Products, H2 2013 28
Number of Products by Top 10 Target, H2 2013 29
Number of Products by Stage and Top 10 Target, H2 2013 30
Number of Products by Top 10 Mechanism of Action, H2 2013 31
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 32
Number of Products by Top 10 Route of Administration, H2 2013 33
Number of Products by Stage and Top 10 Route of Administration, H2 2013 34
Number of Products by Top 10 Molecule Type, H2 2013 35
Number of Products by Stage and Top 10 Molecule Type, H2 2013 36
Number of Products by Top 10 Therapeutic Class, H2 2013 37
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 38



Companies Mentioned

Bayer AG
CSL Limited
LG Life Sciences, Ltd.
ARCA biopharma, Inc.
LegoChem Biosciences, Inc
Zedira GmbH
Navya Biologicals Pvt Ltd
Arromax Pharmatech, Co. Ltd.
China Grand Wuhan General Pharmaceutical Research Institute

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.